Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vasostatin-1 (VS-1) is a bioactive peptide corresponding to the N-terminal fragment (residues 1-78) of Chromogranin A (CgA), an acidic glycoprotein found in the secretory vesicles of neuroendocrine cells. Research, primarily conducted at the San Raffaele Scientific Institute, has identified VS-1 as a potent inhibitor of tumor metastasis and angiogenesis. Its mechanism of action involves the preservation of the VE-cadherin-dependent endothelial barrier function, which effectively inhibits the transendothelial migration and extravasation of circulating tumor cells. In animal models of melanoma and mammary adenocarcinoma, systemic administration of VS-1 has been shown to significantly reduce the formation of lung colonies. Additionally, VS-1 exhibits anti-angiogenic properties by inhibiting vessel formation in various in vitro and in vivo assays.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vasostatin-1.